Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8UZM7
|
|||
| Drug Name |
REGN5678
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 1/2 | [1] | |
| Company |
Regeneron Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03972657) Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.